Are Medical Stocks Lagging Bioventus (BVS) This Year?

Here is how Bioventus (BVS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Zacks Investment Research • Aug 24, 2026

4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike

A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.

Zacks Investment Research • Aug 20, 2026

Is Bioventus (BVS) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Aug 7, 2026

Bioventus Q2 Earnings Call Highlights

Bioventus NASDAQ: BVS reported second-quarter 2026 revenue growth of 4% and reiterated its full-year financial outlook, citing double-digit expansion in its Pain Treatments business, continued debt reduction and increased investment in platelet-rich plasma, peripheral nerve stimulation, Ultrasonics and international operations.

MarketBeat • Aug 5, 2026

Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript

Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 5, 2026

Bioventus Reports Second Quarter Financial Results

DURHAM, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the three and six months ended June 27, 2026.

GlobeNewsWire • Aug 5, 2026

Bioventus (BVS) Q2 Earnings Meet Estimates

Bioventus (BVS) came out with quarterly earnings of $0.22 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.21 per share a year ago.

Zacks Investment Research • Aug 5, 2026

Bioventus to Report Second Quarter of Fiscal Year 2026 Financial Results on August 5, 2026

DURHAM, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2026 before the market opens on Wednesday, August 5, 2026.

GlobeNewsWire • Jul 29, 2026

Bioventus (BVS) to Report Q2 Results: Wall Street Expects Earnings Growth

Bioventus (BVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Jul 29, 2026

Is Bioventus (BVS) Stock Outpacing Its Medical Peers This Year?

Here is how Bioventus (BVS) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Zacks Investment Research • Jul 27, 2026